Actively Recruiting
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Led by National University Hospital, Singapore · Updated on 2024-10-15
3000
Participants Needed
1
Research Sites
339 weeks
Total Duration
On this page
Sponsors
N
National University Hospital, Singapore
Lead Sponsor
N
National University of Singapore
Collaborating Sponsor
AI-Summary
What this Trial Is About
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.
CONDITIONS
Official Title
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 40 and 70 years
- ASCVD (atherosclerotic cardiovascular disease) score of 5% or higher
You will not qualify if you...
- History of major cardiovascular disease such as myocardial infarction, heart failure, or ischemic stroke
- Limited life expectancy
- Ongoing unstable medical conditions
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NUS
Singapore, Singapore
Actively Recruiting
Research Team
H
Hayang Yang, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here